OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic in Saudi Arabia

New Delhi: OneSource Specialty Pharma Limited has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic® (semaglutide) in Saudi Arabia, clearing the pathfor commercialsing the product with Hikma Pharmaceuticals PLC (Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA).

The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.

Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state- of-the-art integratedBiologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based onsales1, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.

Neeraj Sharma, CEO s MD, OneSource Specialty Pharma Limited speaking on the development said: “We areextremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential. We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutionalcustomers.”